Published 6 days ago • loading... • Updated 6 days ago

Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

Summary by cancernetwork.com

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

cancernetwork.com

Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

6 days ago

Read Full Article

europeanreview.org

Impact of pre-transplant serum levels of activin A, activin B, IGF-1 and IL-6 on transplant outcomes and survival in patients with multiple myeloma: a prospective study

OBJECTIVE: This prospective study aimed to assess the impact of activin A/B, interleukin 6 (IL-6) and insulin-like growth factor-1 (IGF-1) on end-organ

6 days ago

Read Full Article